Skip to main content

Table 1 Baseline characteristics

From: Prevalence of venous obstructions in (recurrent) venous thromboembolism: a case-control study

  Recurrent VTE
N = 32
No recurrent VTE
N = 24
P-value
Age, years 68.0 (61.3–72.0) 65.0 (45.3–70.8) 0.223
Sex    0.298
 - Male 28 (87.5) 18 (75.0) 0.298
 - Female 4 (12.5) 6 (25.0) 0.298
Unprovoked DVT 23 (71.9) 10 (41.7) 0.030
Affected side initial event    0.697
 - Left 13 (40.6) 11 (45.8) 0.697
 - Right 19 (59.4) 13 (54.2) 0.697
Affected side recurrent event
 - Ipsilateral (± pulmonary embolism) 17 (53.1) n/a
 - Contralateral (± pulmonary embolism) 9 (28.1) n/a
 - Pulmonary embolism 6 (18.8) n/a
History of pulmonary embolism 8 (25.0)a 4 (16.7)b 0.525
Family history of DVT 10 (31.3) 3 (12.5) 0.122
Antithrombotic therapy 32 (100.0) 17 (70.8) 0.001
Antithrombotic therapy, type    0.071
 - VKA 26 (81.3%) 16 (66.7) 0.212
 - DOACc 6 (18.8%) 0 (0.0) 0.035
Elastic compression stockings, use 19 (59.4) 3 (12.5) < 0.001
  1. Data are n (%) or median (IQR)
  2. DOAC Direct oral anticoagulant, DVT Deep venous thrombosis, LMWH Low Molecular Weight Heparin, n/a Not applicable, VKA Vitamin K Antagonist, VTE Venous Thrombo-Embolism
  3. a All pulmonary embolisms were recurrent VTE which developed after the primary thrombo-embolic event. In 6 patients it presented as a solitary pulmonary embolism and in 2 patients it presented concurrent with a recurrent deep-vein thrombosis
  4. b All pulmonary embolism were concurrent with the primary thrombo-embolic event
  5. c The DOACs used were Rivaroxaban (n = 4), Apixaban (n = 1), and Dabigatran (n = 1)